drug
(cagrilintide + semaglutide)
pre_registrationupdated 6mo agoby Novo Nordisk AS
community read0 votes
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
Trials studying (cagrilintide + semaglutide)
- phase1A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
- phase1A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
- phase3A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- phase3A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
- phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- phase2A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
- phase3A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
- phase2A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
News(10)
- Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deckLAS VEGAS — When Ed Cinca returned to Novo after four years away, he barely recognized the place. “I think the building’s the same, but that’s about it,” Cinca, Novo’s senior vice president of mark…endpoints · 19h ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 1d ago
- Novo’s CagriSema drives more than 20% weight loss at lower dosesAs Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…biospace · 2d ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 6d ago
- Novo gets much-needed lift as Wegovy pill tops Wall Street forecastsThe drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.biopharma_dive · 14d ago
- Novo won't launch CagriSema in Europe for 'a couple of years,' CFO saysNovo won't launch its big obesity hope CagriSema in Europe for another “couple of years,” Novo’s outgoing CFO Karsten Munk Knudsen told Endpoints News in a Wednesday interview. “For CagriSema, the…endpoints · 15d ago
- Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profitsNovo’s CEO has told Fierce that the company remains on the hunt for deals that “close some of the gaps” in its pipeline, as the Big Pharma reports billions of dollars in impairment charges from a s…fiercebiotech · 15d ago
- Novo’s CagriSema achieves 25% weight loss in women, driven by younger patientsPosthoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of patients.biospace · 29d ago
- STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and moreThe median net price for newly launched medicines, when adjusted for inflation and manufacturer discounts, rose by 35% from 2022 to 2025.stat · 1mo ago
- Should amylin have been obesity therapeutics’ primary target from the start?While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 year…biospace · 1mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that